Sudeep Pharma Limited — PPTs, 04-08-2026: Investor Presentation

**Sudeep Pharma Q1 FY27 Performance: Growth Amidst Challenges**

Sudeep Pharma delivered a robust start to FY27, with revenue surging 27% YoY to Rs. 158.3 Cr. This growth was broad-based across Pharma, Food & Nutrition, and Specialty Ingredients, demonstrating resilience despite global headwinds like geopolitical issues and supply chain disruptions. The company is focused on operational excellence and cost management to navigate these challenges.

Key growth initiatives are progressing well. The Greenfield expansion, crucial for enhancing manufacturing capabilities, is on track with customer qualifications advancing. The Sudeep Advanced Materials (SAM) project for battery materials is also moving according to plan, with Phase 2 planning initiated due to strong customer interest. Integration efforts at NSS continue to drive efficiency and profitability.

Financially, EBITDA grew 25% to Rs. 54.9 Cr, and Profit After Tax (PAT) jumped 30% to Rs. 40.6 Cr. The company remains committed to improving capital efficiency through disciplined working capital management. With a diversified portfolio, strong customer relationships, and expanding global reach, Sudeep Pharma is well-positioned for sustainable long-term growth.